| Maximilian Lee, MD | |
|
747 Broadway, Seattle, WA 98122-4379 | |
| (206) 386-6000 | |
| Not Available |
| Full Name | Maximilian Lee |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Gastroenterology |
| Location | 747 Broadway, Seattle, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518143478 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | MD60222397 (Washington) | Primary |
| Entity Name | Stanford Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437292927 PECOS PAC ID: 6709797491 Enrollment ID: O20031124000348 |
News Archive
ViroPharma Incorporated today announced the presentation of data from its Phase 1 study of VP20621 (non-toxigenic Clostridium difficile), a novel treatment approach for preventing recurrent Clostridium difficile infections, a common and dangerous gastrointestinal infection typically occurring in older adults after use of antibiotic medications.
Shire plc, the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease. The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy of VPRIV.
Results from a new survey from the American Heart Association/American Stroke Association found that only half of healthcare professionals consider themselves to be adequately equipped with information about cryptogenic stroke, a stroke in which the underlying cause is still unknown after extensive testing.
Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has submitted the study protocol for the company's Phase IIb trial of ORMD-0801, its oral insulin capsule, to the U.S. Food and Drug Administration.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Maximilian Lee, MD Po Box 25608, Salt Lake City, UT 84125-0608 Ph: (206) 320-4476 | Maximilian Lee, MD 747 Broadway, Seattle, WA 98122-4379 Ph: (206) 386-6000 |
News Archive
ViroPharma Incorporated today announced the presentation of data from its Phase 1 study of VP20621 (non-toxigenic Clostridium difficile), a novel treatment approach for preventing recurrent Clostridium difficile infections, a common and dangerous gastrointestinal infection typically occurring in older adults after use of antibiotic medications.
Shire plc, the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease. The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy of VPRIV.
Results from a new survey from the American Heart Association/American Stroke Association found that only half of healthcare professionals consider themselves to be adequately equipped with information about cryptogenic stroke, a stroke in which the underlying cause is still unknown after extensive testing.
Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has submitted the study protocol for the company's Phase IIb trial of ORMD-0801, its oral insulin capsule, to the U.S. Food and Drug Administration.
› Verified 4 days ago
Sandhya Ramanathan Panch, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 825 Eastlake Ave E, Seattle, WA 98109 Phone: 206-520-5000 | |
Stephen A Lopez, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 925 Seneca St, Seattle, WA 98101 Phone: 206-341-0860 | |
Dr. Susan Hunt, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: Uwmc Department Of Medicine, Box 356429, Seattle, WA 98195 Phone: 206-221-7993 Fax: 206-221-8732 | |
Timothy William Menza, MD, PHD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 325 9th Ave, Seattle, WA 98104 Phone: 206-520-5000 | |
Dr. Vinay Gupta, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1100 9th Ave, Seattle, WA 98101 Phone: 206-223-6980 Fax: 206-223-6982 | |
Dr. Maria Ann Corcorran, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1550 N 115th St, Seattle, WA 98133 Phone: 206-520-5000 | |
Vyshak Alva Venur, M.D Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 825 Eastlake Ave E, Seattle, WA 98109 Phone: 206-520-5700 |